CoChat
Sign Up
Cited by 234Cervical Cancer and HPV ResearchHead and Neck Cancer StudiesEndometrial and Cervical Cancer Treatments

Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype

Open access
Trimble, Cornelia L., Piantadosi, Steven, Gravitt, Patti, Ronnett, Brigitte, Pizer, Ellen, Elko, Andrea, Wilgus, Barbara, Yutzy, William +8 more·2005·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-04-2599PMC PMC3132609
Open this paper in CoChat — free accountOpen PDF

Abstract

Purpose: Persistent infection with oncogenic human papillomaviruses (HPV) plays a central etiologic role in the development of squamous carcinomas of the cervix and their precursor lesions, cervical intraepithelial neoplasias (CIN). We carried out a prospective observational cohort study evaluating known, quantifiable prognostic variables of clinical behavior in women with high-grade cervical lesions. Experimental Design: Our study cohort included healthy women with high-grade cervical lesions (CIN2/3) with residual visible lesions after colposcopically directed biopsy. We prospectively followed 100 women over 15 weeks before standard resection. HPV typing was done using PCR and a reverse line blot detection method. Results: The rate of spontaneous histologic regression, defined as (CIN1 or less at resection) was 28%. The overall rate of HPV infection was 100%. HPV16 was identified in 68% of the lesions. Women with HPV16 only were significantly less likely to regress, compared with women with HPV types other than HPV16 (odds ratio, 0.342; 95% confidence interval, 0.117-0.997; P = 0.049). In the cohort with HPV16 only, patients who had an HLA*A201 allele had similar outcomes to those who did not carry A201. However, among patients with HPV types other than HPV16, the HLA*A201 allele interaction was significant; patients with HLA*A201 were the least likely to resolve. Conclusions: CIN2/3 lesions associated with HPV16 alone are significantly less likely to resolve spontaneously than those caused by other types. Interactions among HPV type, HLA type, and regression rate support a role for HLA-restricted HPV-specific immune responses in determining disease outcome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-2599

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies suggest that a wider range of HPV genotyping may confer additional clinical benefits.

    “previous studies suggest that a wider range of HPV genotyping may confer additional clinical benefits [23, 24]”

    From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [23]

    The Results report different regression rates for HPV16-related types and other HPV types in women with CIN2/3, and the Discussion suggests that future trials may need HPV-based stratification if the findings are validated. This supports a possible prognostic use for broader genotyping, but the paper does not show that expanding genotyping provides clinical benefits in patient care. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infec- tion in young women. NEnglJMed1998;338:423 ^8.
  2. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252 ^8.
  3. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92: 727 ^35.
  4. Nasiell K, Nasiell M, Vaclavinkova V. Behavior of moderate cervical dysplasia during long-term follow- up. Obstet Gynecol 1983;61:609 ^14.
  5. Stoler MH, Schiffman M. Interobserver reproducibili- ty of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500 ^5.
  6. Woodhouse SL, Stastny JF, Styer PE, Kennedy M, Praestgaard AH, Davey DD. Interobserver variability in subclassification of squamous intraepithelial lesions: results of the College of American Pathologists Interlaboratory Comparison Program in Cervicovagi- nal Cytology. Arch Pathol Lab Med Nov 1999;123: 1079 ^84.
  7. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single- hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020 ^7.
  8. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357 ^61.
  9. Gravitt PE. Reproducibility of HPV16 and HPV18 viral load quantitation usingTaqman real-time PCR assays. J Virol Methods 2003;112:23 ^33.
  10. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods Feb 2001;91:109 ^17.
  11. Narod SA,Thompson DW, Jain M,Wall C, Green LM, Miller AB. Dysplasia and the natural history of cervical cancer: early results of theToronto Cohort Study. EurJ Cancer 1991;27:1411 ^6.
  12. Follen M, Atkinson EN, Schottenfeld D, et al. A randomized clinical trial of 4-hydroxyphenylreti- namide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 2001;7: 3356 ^65.
  13. Keefe KA, Schell MJ, Brewer C, et al. A randomized, double blind, Phase III trial using oral h-carotene sup- plementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2001;10:1029 ^35.
  14. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion devel- opment in young females. JAMA 2001;285: 2995 ^3002.
  15. Kjaer S.Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervi- cal squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 14 September 2002;325:572 ^8.
  16. DalsteinV, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for develop- ment of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer Sep 1 2003;106: 396 ^403.
  17. Enomoto T, Haba T, Fujita M, et al. Clonal anal- ysis of high-grade squamous intra-epithelial lesions of the uterine cervix. Int J Cancer 1997;73: 339 ^44.
  18. ParkTW, Richart RM, Sun XW, Wright TC Jr. Asso- ciation between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions. J Natl Cancer Inst 1996;88:355 ^8.
  19. Herrero R, Hildesheim A, Bratti C, et al. Population- based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst Mar 15 2000;92:464 ^74.
  20. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in wom- en with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer Jul 15 2000;87:221 ^7.
  21. Molano M, Posso H, Weiderpass E, et al. Preva- lence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer Jul 29 2002;87:324 ^33.
  22. Sherman ME,Wang SS,Wheeler CM, et al. Determi- nants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev Oct 2003;12: 1038 ^44.
  23. Alric LFM, Izopet J,Vinel J, et al. Genes of the major histocompatibility complex class II influence the out- come of hepatitis C virus infection. Gastroenterology 1997;113:1675 ^81.
  24. Thio CL,Thomas DL, Karacki P, et al. Comprehensive analysis of class I and class II HLA antigens and chron- ic hepatitis B virus infection. J Virol Nov 2003;77: 12083 ^7.
  25. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med Jul 2003;9:928 ^35.
  26. Sarantopoulos S, Lu L, Cantor H. Qa-1restriction of CD8+ suppressor T cells. J Clin Invest Nov 2004; 114:1218 ^21.
  27. Kumar V. Homeostatic control of immunity by TCR peptide-specific Tregs. J Clin Invest Nov 2004; 114:1222 ^6.
  28. Jiang H, Chess L. An integrated view of suppres- sor T cell subsets in immunoregulation. J Clin Invest Nov 2004;114:1198 ^208.
  29. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepa- titis C virus infection. Science Aug 6 2004;305: 872 ^4.
  30. Brabin L. Interactions of the female hormonal en- vironment, susceptibility to viral infections, and dis- ease progression. AIDS Patient Care STDS 2002; 16:211 ^21.
  31. Franklin RD, Kutteh WH. Characterization of immu- noglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999;42:93 ^106.
  32. Ylitalo N, Sorensen P, Josefsson A, et al. Smoking and oral contraceptives as risk factors for cervical car- cinoma in situ. Int J Cancer 1999;81:357 ^65.
  33. Winkelstein W Jr. Smoking and cervical cancerö current status: a review. Am J Epidemiol 1990;131: 945 ^57; discussion 958 ^60.
  34. Szarewski A, Jarvis MJ, Sasieni P, et al. Effect of smoking cessation on cervical lesion size. Lancet 1996;347:941 ^3.
  35. Szarewski A, Maddox P, Royston P, et al. The effect of stopping smoking on cervical Langerhans'cells and lymphocytes. BJOG 2001;108:295 ^303.
  36. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359:1085 ^92.
  37. Gram IT, Austin H, Stalsberg H. Cigarette smoking and the incidence of cervical intraepithelial neoplasia, grade III, and cancer of the cervix uteri. AmJ Epidemiol 1992;135:341 ^6.
  38. Ho GY, Kadish AS, Burk RD, et al. HPV 16 and cigarette smoking as risk factors for high-grade cer- vical intra-epithelial neoplasia. Int J Cancer 1998; 78:281 ^5.
  39. Eppel W, Worda C, Frigo P, Manavi M, Czerwenka K.The influence of cotinine on interleukin 6 expression in smokers with cervical preneoplasia. Acta Obstet Gynecol Scand 2000;79:1105 ^11.
  40. McCann MF, Irwin DE, Walton LA, Hulka BS, Morton JL, Axelrad CM. Nicotine and cotinine in the cervical mucus of smokers, passive smokers, and nonsmokers. Cancer Epidemiol Biomarkers Prev 1992;1:125 ^9.
  41. Poppe WA, Peeters R, Daenens P, Ide PS, Van Assche FA. Tobacco smoking and the uterine cervix: cotinine in blood, urine and cervical fluid. Gynecol Obstet Invest 1995;39:110 ^4.
  42. Prokopczyk B, Cox JE, Hoffmann D, Waggoner SE. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 1997;89:868 ^73.
  43. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78: 123 ^9.
  44. Follen M, Schottenfeld D. Surrogate endpoint biomarkers and their modulation in cervical che- moprevention trials. Cancer 2001;91:1758 ^76.

Cited by

Sorted by citations

Authors
Trimble, C. L., Piantadosi, S., Gravitt, P., Ronnett, B., Pizer, E., Elko, A., Wilgus, B., Yutzy, W., Daniel, R., Shah, K., Peng, S., Hung, C., Roden, R., Wu, T. C., Pardoll, D., & The Johns Hopkins Medical Institutions, B.
Affiliations
  • 1Gynecology and Obstetrics, Departments of
  • 2Oncology, and
  • Johns Hopkins University (US)
  • 3Pathology, Johns Hopkins Medical Institutions and
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2005-07-01
Volume
11
Issue
13
Pages
4717-4723
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-04-2599
PMC
PMC3132609
OpenAlex
W2107415042
Cited by
234
References
1
Citations by year
2026: 3 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 12 · 2021: 10 · 2020: 7 · 2019: 13 · 2018: 19 · 2017: 16 · 2016: 9 · 2015: 15 · 2014: 9 · 2013: 21 · 2012: 15
FWCI
8.17
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Johns Hopkins University
  • National Cancer Institute (K23CA085437, R01CA142691, K23CA85437)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
cervical intraepithelial neoplasia, high-grade cervical dysplasia, spontaneous regression, HPV16, HLA phenotypes, prognostic factors, cervical cancer precursors
MeSH terms
Adolescent, Adult, Aged, Alleles, Uterine Cervical Dysplasia, DNA, Viral, Female, Genotype, HLA Antigens, Humans, Middle Aged, Prospective Studies, Remission, Spontaneous, Cohort Studies, HLA-A2 Antigen, K562 Cells, Papillomaviridae, Papillomavirus Infections, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review